Sather Financial Group Inc Sells 22 Shares of Eli Lilly and Company (NYSE:LLY)

Sather Financial Group Inc cut its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,741 shares of the company’s stock after selling 22 shares during the period. Sather Financial Group Inc’s holdings in Eli Lilly and Company were worth $1,542,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Schear Investment Advisers LLC increased its position in shares of Eli Lilly and Company by 8.9% during the third quarter. Schear Investment Advisers LLC now owns 8,396 shares of the company’s stock valued at $7,438,000 after purchasing an additional 687 shares during the period. WESPAC Advisors SoCal LLC increased its position in shares of Eli Lilly and Company by 8.4% during the third quarter. WESPAC Advisors SoCal LLC now owns 16,676 shares of the company’s stock valued at $14,774,000 after purchasing an additional 1,290 shares during the period. Turtle Creek Wealth Advisors LLC increased its position in shares of Eli Lilly and Company by 1.7% during the third quarter. Turtle Creek Wealth Advisors LLC now owns 5,243 shares of the company’s stock valued at $4,645,000 after purchasing an additional 86 shares during the period. LJI Wealth Management LLC increased its position in shares of Eli Lilly and Company by 3.6% during the third quarter. LJI Wealth Management LLC now owns 7,004 shares of the company’s stock valued at $6,205,000 after purchasing an additional 246 shares during the period. Finally, Heritage Investment Group Inc. increased its position in shares of Eli Lilly and Company by 3.9% during the third quarter. Heritage Investment Group Inc. now owns 2,126 shares of the company’s stock valued at $1,884,000 after purchasing an additional 79 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on LLY. Wells Fargo & Company boosted their price objective on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research report on Friday, August 9th. Barclays decreased their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research note on Thursday, October 31st. Sanford C. Bernstein started coverage on Eli Lilly and Company in a research note on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price target on the stock. Guggenheim boosted their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Finally, Truist Financial boosted their price target on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. Four investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,007.94.

Eli Lilly and Company Trading Down 4.9 %

Shares of LLY opened at $746.20 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a 12-month low of $561.65 and a 12-month high of $972.53. The firm has a market capitalization of $708.38 billion, a PE ratio of 80.67, a price-to-earnings-growth ratio of 2.82 and a beta of 0.43. The stock’s fifty day simple moving average is $882.65 and its 200-day simple moving average is $870.38.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The firm had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. During the same period last year, the company earned $0.10 EPS. The company’s revenue was up 20.4% compared to the same quarter last year. As a group, research analysts predict that Eli Lilly and Company will post 13.21 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 0.70%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the sale, the chief accounting officer now owns 5,480 shares in the company, valued at approximately $4,402,522.40. This represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.